{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:21:23Z","timestamp":1791325283014,"version":"4.3.1"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371411"],"award-info":[{"award-number":["82371411"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.biopha.2025.118525","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T10:29:47Z","timestamp":1757500187000},"page":"118525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["The pathogenesis of immune-mediated necrotizing myopathy: Progress and therapeutic implications"],"prefix":"10.1016","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7623-1022","authenticated-orcid":false,"given":"Mengge","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuajin","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayang","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huajie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouping","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bitao","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.biopha.2025.118525_bib1","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/art.41762","article-title":"Expert perspective: management of refractory inflammatory myopathy","volume":"73","author":"Lundberg","year":"2021","journal-title":"Arthritis Rheuma"},{"issue":"5","key":"10.1016\/j.biopha.2025.118525_bib2","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/WCO.0000000000000740","article-title":"Classification of idiopathic inflammatory myopathies: pathology perspectives","volume":"32","author":"Tanboon","year":"2019","journal-title":"Curr. Opin. Neurol."},{"issue":"24","key":"10.1016\/j.biopha.2025.118525_bib3","doi-asserted-by":"crossref","first-page":"9507","DOI":"10.1073\/pnas.83.24.9507","article-title":"Human autoantibodies reactive with the signal-recognition particle","volume":"83","author":"Reeves","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.biopha.2025.118525_bib4","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, naarden, the Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul. Disord."},{"issue":"9","key":"10.1016\/j.biopha.2025.118525_bib5","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.27572","article-title":"A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy","volume":"62","author":"Christopher-Stine","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.biopha.2025.118525_bib6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"224th ENMC international workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies zandvoort, the Netherlands, 14-16 October 2016","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscul. Disord. NMD"},{"key":"10.1016\/j.biopha.2025.118525_bib7","doi-asserted-by":"crossref","first-page":"1094611","DOI":"10.3389\/fimmu.2023.1094611","article-title":"Characteristics of cardiac involvement in immune-mediated necrotizing myopathy","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118525_bib8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12890-021-01802-1","article-title":"Interstitial lung disease is not rare in immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies","volume":"22","author":"Ge","year":"2022","journal-title":"BMC Pulm. Med."},{"issue":"21","key":"10.1016\/j.biopha.2025.118525_bib9","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3390\/jcm11216566","article-title":"The clinicopathological distinction between Immune-Mediated necrotizing myopathy and Limb-Girdle muscular dystrophy R2: key points to prevent misdiagnosis","volume":"11","author":"Yang","year":"2022","journal-title":"J. Clin. Med."},{"issue":"12","key":"10.1016\/j.biopha.2025.118525_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103468","article-title":"Anti-HMGCR immune-mediated necrotising myopathy: addressing the remaining issues","volume":"22","author":"Khoo","year":"2023","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.biopha.2025.118525_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113936","article-title":"The pathogenesis of anti-signal recognition particle necrotizing myopathy: a review","volume":"156","author":"Qiu","year":"2022","journal-title":"Biomed. Pharm."},{"issue":"6583","key":"10.1016\/j.biopha.2025.118525_bib12","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1126\/science.abl6459","article-title":"Mechanism of signal sequence handover from NAC to SRP on ribosomes during ER-protein targeting","volume":"375","author":"Jomaa","year":"2022","journal-title":"Science (New York NY)"},{"issue":"6","key":"10.1016\/j.biopha.2025.118525_bib13","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/00002281-199711000-00008","article-title":"Classification criteria for the idiopathic inflammatory myopathies","volume":"9","author":"Targoff","year":"1997","journal-title":"Curr. Opin. Rheumatol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118525_bib14","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/jnnp.73.4.420","article-title":"Myopathy with antibodies to the signal recognition particle: clinical and pathological features","volume":"73","author":"Miller","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"12","key":"10.1016\/j.biopha.2025.118525_bib15","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1136\/ard.2006.052191","article-title":"Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy","volume":"65","author":"Hengstman","year":"2006","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.biopha.2025.118525_bib16","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.nmd.2014.01.002","article-title":"Myopathy with anti-signal recognition particle antibodies: clinical and histopathological features in Chinese patients","volume":"24","author":"Wang","year":"2014","journal-title":"Neuromuscul. Disord. NMD"},{"issue":"7","key":"10.1016\/j.biopha.2025.118525_bib17","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/art.30344","article-title":"Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy","volume":"63","author":"Benveniste","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.biopha.2025.118525_bib18","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1093\/rheumatology\/keab629","article-title":"Plasma exchange therapy in refractory inflammatory myopathy with anti-signal recognition particle antibody: a case series","volume":"61","author":"Zhang","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.biopha.2025.118525_bib19","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/jca.21968","article-title":"Therapeutic plasma exchange for the treatment of refractory necrotizing autoimmune myopathy","volume":"37","author":"Kruse","year":"2022","journal-title":"J. Clin. Apher."},{"issue":"3","key":"10.1016\/j.biopha.2025.118525_bib20","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme a reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.biopha.2025.118525_bib21","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.autrev.2016.07.023","article-title":"Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: a history of statins and experience from a large international multi-center study","volume":"15","author":"Musset","year":"2016","journal-title":"Autoimmun. Rev."},{"issue":"3","key":"10.1016\/j.biopha.2025.118525_bib22","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/MD.0000000000000028","article-title":"Anti-HMGCR autoantibodies in european patients with autoimmune necrotizing myopathies: inconstant exposure to statin","volume":"93","author":"Allenbach","year":"2014","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.biopha.2025.118525_bib23","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/BOR.0000000000000106","article-title":"Necrotizing myopathies: beyond statins","volume":"26","author":"Mammen","year":"2014","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.biopha.2025.118525_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.866701","article-title":"Screening for Anti-HMGCR antibodies in a large single myositis center reveals infrequent exposure to statins and diversiform presentation of the disease","volume":"13","author":"Szczesny","year":"2022","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118525_bib25","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1002\/art.34673","article-title":"Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase-associated autoimmune myopathy","volume":"64","author":"Werner","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.biopha.2025.118525_bib26","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/ana.24902","article-title":"Pathogenic role of anti-signal recognition protein and anti-3-Hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies","volume":"81","author":"Arouche-Delaperche","year":"2017","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118525_bib27","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/annrheumdis-2018-213518","article-title":"In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy","volume":"78","author":"Bergua","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.biopha.2025.118525_bib28","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.bbrc.2015.09.065","article-title":"Skeletal muscle-specific HMG-CoA reductase knockout mice exhibit rhabdomyolysis: a model for statin-induced myopathy","volume":"466","author":"Osaki","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1-2","key":"10.1016\/j.biopha.2025.118525_bib29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jneuroim.2013.08.008","article-title":"Complement-mediated muscle cell lysis: a possible mechanism of myonecrosis in anti-SRP associated necrotizing myopathy (ASANM)","volume":"264","author":"Rojana-udomsart","year":"2013","journal-title":"J. Neuroimmunol."},{"issue":"11","key":"10.1016\/j.biopha.2025.118525_bib30","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/ard-2024-225773","article-title":"Pathological autoantibody internalisation in myositis","volume":"83","author":"Pinal-Fernandez","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biopha.2025.118525_bib31","article-title":"In immune-mediated necrotising myopathy, anti-HMGCR antibodies inhibit HMGCR activity, leading to the sarcoplasmic accumulation of lipid droplets and myofibres necrosis","volume":"2025","author":"Giannini","year":"2025","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.biopha.2025.118525_bib32","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.ajpath.2020.02.006","article-title":"Complement membrane attack complex: new roles, mechanisms of action, and therapeutic targets","volume":"190","author":"Xie","year":"2020","journal-title":"Am. J. Pathol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118525_bib33","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1212\/WNL.0000000000004923","article-title":"Necrosis in anti-SRP+ and anti-HMGCR+myopathies: role of autoantibodies and complement","volume":"90","author":"Allenbach","year":"2018","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.biopha.2025.118525_bib34","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3390\/biomedicines10082036","article-title":"Prevention of Anti-HMGCR Immune-Mediated necrotising myopathy by C5 complement inhibition in a humanised mouse model","volume":"10","author":"Julien","year":"2022","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.biopha.2025.118525_bib35","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S2665-9913(23)00003-6","article-title":"Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial","volume":"5","author":"Mammen","year":"2023","journal-title":"Lancet Rheuma"},{"key":"10.1016\/j.biopha.2025.118525_bib36","article-title":"Immune-mediated necrotizing myopathy (IMNM): a myopathological challenge","volume":"2021","author":"Merlonghi","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.biopha.2025.118525_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2022.577833","article-title":"Serum cytokine and chemokine profiles in patients with immune-mediated necrotizing myopathy","volume":"365","author":"Oda","year":"2022","journal-title":"J. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118525_bib38","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/rheumatology\/keae118","article-title":"Interleukin-6 trans-signalling regulates monocyte chemoattractant protein-1 production in immune-mediated necrotizing myopathy","volume":"64","author":"Ma","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.biopha.2025.118525_bib39","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1093\/rheumatology\/kead108","article-title":"TWEAK and Fn14 are overexpressed in immune-mediated necrotizing myopathy: implications for muscle damage and repair","volume":"62","author":"Yang","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.biopha.2025.118525_bib40","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1089\/ars.2017.7420","article-title":"The role of metabolic remodeling in macrophage polarization and its effect on skeletal muscle regeneration","volume":"30","author":"De Santa","year":"2019","journal-title":"Antioxid. Redox Signal"},{"issue":"6","key":"10.1016\/j.biopha.2025.118525_bib41","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.ajpath.2012.08.033","article-title":"Immune-mediated necrotizing myopathy is characterized by a specific Th1-M1 polarized immune profile","volume":"181","author":"Preu\u00dfe","year":"2012","journal-title":"Am. J. Pathol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118525_bib42","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000558","article-title":"PD1 pathway in immune-mediated myopathies: pathogenesis of dysfunctional t cells revisited","volume":"6","author":"Knauss","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"8","key":"10.1016\/j.biopha.2025.118525_bib43","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1093\/rheumatology\/keab900","article-title":"Perivascular and endomysial macrophages expressing VEGF and CXCL12 promote angiogenesis in anti-HMGCR immune-mediated necrotizing myopathy","volume":"61","author":"Lia","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.biopha.2025.118525_bib44","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/acn3.52065","article-title":"CD163+ macrophage density in perimysial connective tissue associated with prognosis in IMNM","volume":"11","author":"Sun","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118525_bib45","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/j.cmet.2020.05.004","article-title":"Endothelial lactate controls muscle regeneration from ischemia by inducing M2-like macrophage polarization","volume":"31","author":"Zhang","year":"2020","journal-title":"Cell Metab."},{"issue":"6","key":"10.1016\/j.biopha.2025.118525_bib46","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/cdd.2015.171","article-title":"Cell death, clearance and immunity in the skeletal muscle","volume":"23","author":"Sciorati","year":"2016","journal-title":"Cell Death Differ."},{"issue":"2","key":"10.1016\/j.biopha.2025.118525_bib47","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1136\/ard-2024-225732","article-title":"Precise identification and tracking of HMGCR-reactive CD4+ t cells in the target tissue of patients with anti-HMGCR immune-mediated necrotising myopathy","volume":"84","author":"Tiniakou","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biopha.2025.118525_bib48","article-title":"Management of immune-mediated necrotizing myopathy","volume":"2024","author":"Suh","year":"2024","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.biopha.2025.118525_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.cytox.2022.100063","article-title":"An exploratory study of circulating cytokines and chemokines in patients with muscle disorders proposes CD40L and CCL5 represent general disease markers while CXCL10 differentiates between patients with an autoimmune myositis","volume":"4","author":"De Paepe","year":"2022","journal-title":"Cytokine X"},{"issue":"5","key":"10.1016\/j.biopha.2025.118525_bib50","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.autrev.2017.12.005","article-title":"Skeletal muscle cells actively shape (auto)immune responses","volume":"17","author":"Afzali","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.biopha.2025.118525_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2018.12.005","article-title":"Targeting the CD40-CD40L pathway in autoimmune diseases: humoral immunity and beyond","volume":"141","author":"Karnell","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"7","key":"10.1016\/j.biopha.2025.118525_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103120","article-title":"Significance of IL-7 and IL-7R in RA and autoimmunity","volume":"21","author":"Meyer","year":"2022","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2025.118525_bib53","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cmet.2007.11.011","article-title":"Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy","volume":"7","author":"Serrano","year":"2008","journal-title":"Cell Metab."},{"issue":"4","key":"10.1016\/j.biopha.2025.118525_bib54","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1091\/mbc.e03-08-0585","article-title":"p38 MAPK-induced nuclear factor-kappaB activity is required for skeletal muscle differentiation: role of interleukin-6","volume":"15","author":"Baeza-Raja","year":"2004","journal-title":"Mol. Biol. Cell"},{"issue":"17","key":"10.1016\/j.biopha.2025.118525_bib55","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1111\/febs.12338","article-title":"Interleukin-6 myokine signaling in skeletal muscle: a double-edged sword?","volume":"280","author":"Mu\u00f1oz-C\u00e1noves","year":"2013","journal-title":"FEBS J."},{"issue":"1","key":"10.1016\/j.biopha.2025.118525_bib56","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.nmd.2012.09.001","article-title":"Pipestem capillaries in necrotizing myopathy revisited","volume":"23","author":"Schr\u00f6der","year":"2013","journal-title":"Neuromuscul. Disord. NMD"},{"issue":"93","key":"10.1016\/j.biopha.2025.118525_bib57","article-title":"Effects of topical icing on inflammation, angiogenesis, revascularization, and myofiber regeneration in skeletal muscle following contusion injury","volume":"8","author":"Singh","year":"2017","journal-title":"Front. Physiol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118525_bib58","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/s41422-020-00393-6","article-title":"Myofiber necroptosis promotes muscle stem cell proliferation via releasing Tenascin-C during regeneration","volume":"30","author":"Zhou","year":"2020","journal-title":"Cell Res."},{"issue":"4","key":"10.1016\/j.biopha.2025.118525_bib59","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.stemcr.2020.08.002","article-title":"Damaged myofiber-derived metabolic enzymes act as activators of muscle satellite cells","volume":"15","author":"Tsuchiya","year":"2020","journal-title":"Stem Cell Rep."},{"issue":"6","key":"10.1016\/j.biopha.2025.118525_bib60","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41580-018-0003-4","article-title":"Mechanism and medical implications of mammalian autophagy","volume":"19","author":"Dikic","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2025.118525_bib61","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1016\/j.csbj.2023.03.019","article-title":"Identification of feature genes and key biological pathways in immune-mediated necrotizing myopathy: High-throughput sequencing and bioinformatics analysis","volume":"21","author":"Chen","year":"2023","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"3","key":"10.1016\/j.biopha.2025.118525_bib62","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.nmd.2018.01.004","article-title":"Mitophagy in three cases of immune-mediated necrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase autoantibodies: ultrastructural and immunohistochemical studies","volume":"28","author":"Matsubara","year":"2018","journal-title":"Neuromuscul. Disord. NMD"},{"issue":"3","key":"10.1016\/j.biopha.2025.118525_bib63","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/mus.26608","article-title":"Autophagy markers LC3 and p62 accumulate in immune-mediated necrotizing myopathy","volume":"60","author":"Girolamo","year":"2019","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.biopha.2025.118525_bib64","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1002\/jcsm.13000","article-title":"Autophagy in muscle regeneration: potential therapies for myopathies","volume":"13","author":"Chen","year":"2022","journal-title":"J. Cachex.. Sarcopenia Muscle"},{"issue":"2","key":"10.1016\/j.biopha.2025.118525_bib65","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1042\/BJ20140312","article-title":"Autophagy is required and protects against apoptosis during myoblast differentiation","volume":"462","author":"McMillan","year":"2014","journal-title":"Biochem. J."},{"issue":"11","key":"10.1016\/j.biopha.2025.118525_bib66","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201708799","article-title":"Rapamycin rescues mitochondrial myopathy via coordinated activation of autophagy and lysosomal biogenesis","volume":"10","author":"Civiletto","year":"2018","journal-title":"EMBO Mol. Med."},{"issue":"9","key":"10.1016\/j.biopha.2025.118525_bib67","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41591-018-0131-6","article-title":"The exerkine apelin reverses age-associated sarcopenia","volume":"24","author":"Vinel","year":"2018","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.biopha.2025.118525_bib68","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1096\/fj.13-237388","article-title":"Rapamycin nanoparticles target defective autophagy in muscular dystrophy to enhance both strength and cardiac function","volume":"28","author":"Bibee","year":"2014","journal-title":"FASEB J."},{"key":"10.1016\/j.biopha.2025.118525_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.878755","article-title":"Hidden agenda - the involvement of endoplasmic reticulum stress and unfolded protein response in Inflammation-Induced muscle wasting","volume":"13","author":"Kny","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118525_bib70","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/jcp.25852","article-title":"Emerging roles of ER stress and unfolded protein response pathways in skeletal muscle health and disease","volume":"233","author":"Bohnert","year":"2018","journal-title":"J. Cell Physiol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118525_bib71","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.ajpath.2013.06.003","article-title":"Overexpression of MHC class I in muscle of lymphocyte-deficient mice causes a severe myopathy with induction of the unfolded protein response","volume":"183","author":"Fr\u00e9ret","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.biopha.2025.118525_bib72","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.791986","article-title":"Endoplasmic reticulum stress is involved in muscular pathogenesis in idiopathic inflammatory myopathies","volume":"10","author":"Ma","year":"2022","journal-title":"Front Cell Dev. Biol."},{"key":"10.1016\/j.biopha.2025.118525_bib73","article-title":"Endoplasmic reticulum-stress and unfolded protein response-activation in immune-mediated necrotizing myopathy","volume":"2022","author":"Preusse","year":"2022","journal-title":"Brain Pathol. (Zur. Switz.)"},{"issue":"11","key":"10.1016\/j.biopha.2025.118525_bib74","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1096\/fj.06-6408com","article-title":"Endoplasmic reticulum stress increases myofiber formation in vitro","volume":"21","author":"Nakanishi","year":"2007","journal-title":"FASEB J."},{"issue":"2","key":"10.1016\/j.biopha.2025.118525_bib75","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/febs.14358","article-title":"ER stress in skeletal muscle remodeling and myopathies","volume":"286","author":"Afroze","year":"2019","journal-title":"FEBS J."},{"issue":"3","key":"10.1016\/j.biopha.2025.118525_bib76","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/jcsm.12288","article-title":"The double-edged sword of endoplasmic reticulum stress in uremic sarcopenia through myogenesis perturbation","volume":"9","author":"Jheng","year":"2018","journal-title":"J. Cachex.. Sarcopenia Muscle"},{"issue":"24","key":"10.1016\/j.biopha.2025.118525_bib77","doi-asserted-by":"crossref","first-page":"6032","DOI":"10.1111\/jcmm.17621","article-title":"Major histocompatibility complex I-induced endoplasmic reticulum stress mediates the secretion of pro-inflammatory muscle-derived cytokines","volume":"26","author":"Thoma","year":"2022","journal-title":"J. Cell Mol. Med."},{"issue":"3","key":"10.1016\/j.biopha.2025.118525_bib78","doi-asserted-by":"crossref","first-page":"C392","DOI":"10.1152\/ajpcell.00125.2016","article-title":"The ubiquitin proteasome system in atrophying skeletal muscle: roles and regulation","volume":"311","author":"Bilodeau","year":"2016","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.biopha.2025.118525_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.1032738","article-title":"The accumulation of muscle RING finger-1 in regenerating myofibers: implications for muscle repair in immune-mediated necrotizing myopathy","volume":"13","author":"Yang","year":"2022","journal-title":"Front Neurol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118525_bib80","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1083\/jcb.200108089","article-title":"Muscle-specific RING finger-1 interacts with titin to regulate sarcomeric M-line and thick filament structure and May have nuclear functions via its interaction with glucocorticoid modulatory element binding protein-1","volume":"157","author":"McElhinny","year":"2002","journal-title":"J. Cell Biol."},{"issue":"6-8","key":"10.1016\/j.biopha.2025.118525_bib81","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10974-005-9021-x","article-title":"Functional properties of the titin\/connectin-associated proteins, the muscle-specific RING finger proteins (MURFs), in striated muscle","volume":"26","author":"Gregorio","year":"2005","journal-title":"J. Muscle Res. Cell Motil."},{"key":"10.1016\/j.biopha.2025.118525_bib82","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejim.2022.04.017","article-title":"Epidemiological and genetic features of anti-3\u2011hydroxy-3-methylglutaryl-CoA reductase necrotizing myopathy: single-center experience and literature review","volume":"101","author":"Prieto-Pe\u00f1a","year":"2022","journal-title":"Eur. J. Intern. Med."},{"issue":"5","key":"10.1016\/j.biopha.2025.118525_bib83","doi-asserted-by":"crossref","first-page":"363","DOI":"10.5692\/clinicalneurol.cn-001684","article-title":"A case of anti-SRP antibody-positive immune-mediated necrotizing myopathy triggered by human parvovirus B19 infection","volume":"62","author":"Suzuki","year":"2022","journal-title":"Rinsho Shinkeigaku"},{"issue":"2","key":"10.1016\/j.biopha.2025.118525_bib84","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00296-022-05230-0","article-title":"Challenges in the diagnosis and management of immune-mediated necrotising myopathy (IMNM) in a patient on long-term statins","volume":"43","author":"Khan","year":"2023","journal-title":"Rheuma Int"},{"issue":"18","key":"10.1016\/j.biopha.2025.118525_bib85","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1212\/WNL.0000000000003160","article-title":"HLA-DRB1 alleles in immune-mediated necrotizing myopathy","volume":"87","author":"Ohnuki","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.biopha.2025.118525_bib86","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejim.2023.05.011","article-title":"Therapeutic challenges and cardiovascular risk in patients with HMGCR-associated immune-mediated necrotizing myopathy (HMGR-IMNM) secondary to statins","volume":"114","author":"\u00c1lvarez-Troncoso","year":"2023","journal-title":"Eur. J. Intern Med"},{"issue":"5","key":"10.1016\/j.biopha.2025.118525_bib87","article-title":"Absence of pathogenic mutations and strong association with HLA-DRB1*11:01 in Statin-Na\u00efve Early-Onset Anti-HMGCR necrotizing myopathy","volume":"11","author":"Llans\u00f3","year":"2024","journal-title":"Neurol. (R.) Neuroimmunol. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.biopha.2025.118525_bib88","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/tan.14950","article-title":"Association of immune-mediated necrotizing myopathy with HLA polymorphisms","volume":"101","author":"Ohnuki","year":"2023","journal-title":"HLA"},{"issue":"1","key":"10.1016\/j.biopha.2025.118525_bib89","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40478-023-01518-9","article-title":"Molecular signatures of inherited and acquired sporadic late onset nemaline myopathies","volume":"11","author":"Nicolau","year":"2023","journal-title":"Acta Neuropathol. Commun."},{"issue":"2","key":"10.1016\/j.biopha.2025.118525_bib90","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.semarthrit.2019.03.005","article-title":"Novel susceptibility alleles in HLA region for myositis and myositis specific autoantibodies in Korean patients","volume":"49","author":"Kang","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.biopha.2025.118525_bib91","article-title":"miR-18a-3p and its target protein HuR May regulate myogenic differentiation in Immune-Mediated necrotizing myopathy","volume":"12","author":"Ye","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2025.118525_bib92","doi-asserted-by":"crossref","DOI":"10.1177\/1756286421998918","article-title":"Rituximab in the treatment of immune-mediated necrotizing myopathy: a review of case reports and case series","author":"Xiong","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"6","key":"10.1016\/j.biopha.2025.118525_bib93","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3899\/jrheum.171495","article-title":"Rituximab in the treatment of refractory Anti-HMGCR immune-mediated necrotizing myopathy","volume":"46","author":"Landon-Cardinal","year":"2019","journal-title":"J. Rheuma"},{"issue":"1","key":"10.1016\/j.biopha.2025.118525_bib94","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/CND.0000000000000248","article-title":"Favorable response in Statin-Naive paraneoplastic Anti-HMGCR Antibody-Associated myopathy to single dose of rituximab and persistent remission with management of underlying lung cancer","volume":"21","author":"Waheed","year":"2019","journal-title":"J. Clin. Neuromuscul. Dis."},{"issue":"5","key":"10.1016\/j.biopha.2025.118525_bib95","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1136\/practneurol-2018-002168","article-title":"Difficult case: rituximab in anti-SRP antibody myositis in pregnancy","volume":"19","author":"Mehta","year":"2019","journal-title":"Pr. Neurol."},{"key":"10.1016\/j.biopha.2025.118525_bib96","doi-asserted-by":"crossref","first-page":"1301109","DOI":"10.3389\/fimmu.2023.1301109","article-title":"Anti-SRP immune-mediated necrotizing myopathy responsive to ofatumumab: a case report","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2025.118525_bib97","article-title":"Daratumumab as a rescue therapy in severe refractory anti-SRP immune-mediated necrotising myopathy","volume":"2023","author":"Landon-Cardinal","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2025.118525_bib98","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2024.3818","article-title":"Current and future roles of chimeric antigen receptor T-Cell therapy in neurology: a review","volume":"82","author":"Ismail","year":"2025","journal-title":"JAMA Neurol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118525_bib99","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2315990121","article-title":"Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy","volume":"121","author":"Qin","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2025.118525_bib100","article-title":"Case study of CD19 CAR t therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-Myositis phase I\/II trial","volume":"2024","author":"Volkov","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2025.118525_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103291","article-title":"Telitacicept: a novel horizon in targeting autoimmunity and rheumatic diseases","volume":"148","author":"Zeng","year":"2024","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.biopha.2025.118525_bib102","article-title":"Telitacicept add-on therapy in refractory idiopathic inflammatory myopathy: insights from a pilot study","volume":"2024","author":"Gao","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.biopha.2025.118525_bib103","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.777502","article-title":"Belimumab for Immune-Mediated necrotizing myopathy associated with Anti-SRP antibodies: a case report and retrospective review of patients treated with Anti-B-Cell therapy in a single center and literature","volume":"12","author":"Cui","year":"2021","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.biopha.2025.118525_bib104","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"issue":"10413","key":"10.1016\/j.biopha.2025.118525_bib105","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1016\/S0140-6736(23)01460-5","article-title":"Efficacy and safety of the neonatal fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Broome","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2025.118525_bib106","article-title":"Treatment of refractory immune-mediated necrotizing myopathy with efgartigimod","volume":"15","author":"Yang","year":"2024","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118525_bib107","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1093\/rheumatology\/kead298","article-title":"Efgartigimod restores muscle function in a humanized mouse model of immune-mediated necrotizing myopathy","volume":"62","author":"Julien","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.biopha.2025.118525_bib108","article-title":"The efficacy of tocilizumab in the treatment of patients with refractory Immune-Mediated necrotizing myopathies: an Open-Label pilot study","volume":"12","author":"Li","year":"2021","journal-title":"Front. Pharm."},{"issue":"5","key":"10.1016\/j.biopha.2025.118525_bib109","first-page":"740","article-title":"Tacrolimus combined with corticosteroids effectively improved the outcome of a cohort of patients with immune-mediated necrotising myopathy","volume":"37","author":"Feng","year":"2019","journal-title":"Clin. Exp. Rheuma"},{"key":"10.1016\/j.biopha.2025.118525_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2025.105363","article-title":"Emerging atypical clinicopathological manifestations of immune-mediated necrotizing myopathy (IMNM)","volume":"50","author":"Skolka","year":"2025","journal-title":"Neuromuscul. Disord. NMD"},{"key":"10.1016\/j.biopha.2025.118525_bib111","doi-asserted-by":"crossref","unstructured":"Stefan N., Margherita M., Jennifer A.T., John R.M., James D.T., Teerin L.J.M.N. Immune-mediated necrotizing myopathy: Unusual presentations of a treatable disease. 2021;64(6). doi:10.1002\/mus.27435 (2021).","DOI":"10.1002\/mus.27435"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222500719X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222500719X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T01:49:30Z","timestamp":1772848170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222500719X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":111,"alternative-id":["S075333222500719X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118525","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The pathogenesis of immune-mediated necrotizing myopathy: Progress and therapeutic implications","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118525","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118525"}}